Vimarsana
Biggest News Aggregation in the World

Page 5 - Upper Limit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Upper Limit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Upper Limit Today - Breaking & Trending Today

Short-handed Kings adjust to the new normal - Vimarsana News

Short-handed Kings adjust to the new normal

Carrying 21 players due to salary cap constraints and down to 19 in uniform for their season opener as a result of Arthur Kaliyev’s suspension and Viktor Arvidsson’s lower-body injury, the Kings’ bench will often be a short one.

Short-handed Kings adjust to their new normal - Vimarsana News

Short-handed Kings adjust to their new normal

Carrying 21 players due to salary cap constraints and down to 19 in uniform for their season opener as a result of Arthur Kaliyev’s suspension and Viktor Arvidsson’s lower-body injury, the Kings’ bench will often be a short one.

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA ... - Vimarsana News

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA ...

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) - Vimarsana News

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 -- Travere Therapeutics, Inc. today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential...

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan - Vimarsana News

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...